Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Emily Z KeungMelissa BurgessRuth SalazarEdwin R ParraJaime Rodrigues-CanalesVanessa CilentoBrian Andrew Van TineScott M SchuetzeSteven AttiaRichard F RiedelJames HuScott H OkunoDennis A PriebatSujana MovvaLara E DavisDamon R ReedAlexandre ReubenChristina L RolandDenise ReinkeAlexander J F LazarWei-Lien WangJennifer A WargoHussein A TawbiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS. Our findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti-PD-1 therapy in specific advanced sarcomas. Efforts to confirm the activity of pembrolizumab in an expansion cohort of patients with UPS/DDLPS are underway.